Literature DB >> 8454873

Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.

P N Friedman1, D F Chace, P A Trail, C B Siegall.   

Abstract

We have constructed a single-chain immunotoxin consisting of the variable H and L chains of the carcinoma-reactive mAb BR96, fused to the binding defective protein toxin, PE40. This molecule, BR96 sFv-PE40, has been shown to be extremely cytotoxic toward a variety of BR96 Ag-expressing tumor cell lines. When administered i.v. into athymic mice carrying L2987 tumor xenografts, BR96 sFv-PE40 was cleared rapidly from the blood with a half-life of approximately 30 min. This is in comparison to a chemical conjugate, chiBR96-LysPE40, that remained in the blood for almost 2 h. In addition, the smaller single-chain immunotoxin (67 kDa) penetrates the tumor faster than the larger chemical conjugate (190 kDa). Using a variety of administration schedules and doses, we treated established human tumor xenografts in athymic mice with both the single-chain immunotoxin BR96 sFv-PE40 and the chemical conjugate chiBR96-LysPE40. In both L2987 lung carcinoma and MCF-7 breast carcinoma models, we found that BR96 sFv-PE40 completely regressed the tumor xenografts. With an administration schedule of q4dx5, the tumors were totally regressed and did not reappear. The chiBR96-LysPE40 conjugate produced partial tumor regressions, although at near maximum tolerated dose. These results show that the single-chain immunotoxin, BR96 sFv-PE40, is a potent antitumor agent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454873

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  10 in total

1.  Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.

Authors:  D C Blakey; P E Pinder; A F Wright
Journal:  Cell Biophys       Date:  1994

2.  In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin.

Authors:  S E Gasanov; E D Rael; N E Gasanov; L P Vernon
Journal:  Cancer Immunol Immunother       Date:  1995-08       Impact factor: 6.968

3.  Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Authors:  I H Pastan; G E Archer; R E McLendon; H S Friedman; H E Fuchs; Q C Wang; L H Pai; J Herndon; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  Bacterial expression and refolding of single-chain Fv fragments with C-terminal cysteines.

Authors:  S M Kipriyanov; S Dübel; F Breitling; R E Kontermann; S Heymann; M Little
Journal:  Cell Biophys       Date:  1995-06

5.  Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.

Authors:  C B Siegall; D Liggitt; D Chace; M A Tepper; H P Fell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

6.  Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.

Authors:  A M Di Massimo; M Di Loreto; A Pacilli; G Raucci; L D'Alatri; A Mele; A Bolognesi; L Polito; F Stirpe; R De Santis
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 7.  Clinical targeting recombinant immunotoxins for cancer therapy.

Authors:  Meng Li; Zeng-Shan Liu; Xi-Lin Liu; Qi Hui; Shi-Ying Lu; Lin-Lin Qu; Yan-Song Li; Yu Zhou; Hong-Lin Ren; Pan Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

8.  A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice.

Authors:  A Lamarre; M W Yu; F Chagnon; P J Talbot
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

9.  Bioinformatics in molecular immunology laboratories demonstrated: Modeling an anti-CMV scFv antibody.

Authors:  Chua Kek Heng; Rofina Yasmin Othman
Journal:  Bioinformation       Date:  2006-03-27

10.  Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.

Authors:  J Garrigues; J Anderson; K E Hellström; I Hellström
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.